OncLive TV

Ulka Vaishampayan, MD, discusses the shifting role of cytoreductive nephrectomy in renal cell carcinoma.

Girish Putcha, MD, PhD, chief medical officer and clinical laboratory director, Freenome, discusses blood-based detection of early-stage colorectal cancer (CRC) using multiomics and machine learning.

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the phase II DESTINY-Breast01 trial in advanced HER2-positive breast cancer.

A. Oliver Sartor, MD, professor of medicine, medical director, Tulane Cancer Center, and C. E. and Bernadine Laborde Professor of Cancer Research, Departments of Medicine and Urology, Tulane University, discusses emerging agents in prostate cancer.

Farrukh Awan, MD, discusses the role of chemotherapy in the treatment of patients with chronic lymphocytic leukemia (CLL).

Girish Putcha, MD, PhD, discusses the use of blood-based screening assays in colorectal cancer (CRC).

Peter Voorhees, MD, discusses the role of CAR T-cell therapy in multiple myeloma.

Amir Khan, MD, discusses trends in the overall incidence of gastric cancer and colorectal cancer.

James M. Reuben, PhD, MBA, discusses the search for biomarkers in patients with metastatic breast cancer.

David Morris, MD, FACS, discusses choosing the best agent to treat patients with nonmetastatic castration-resistant prostate cancer.

Rebecca L. Olin, MD, MSCE, discusses research surrounding FLT3 inhibitors as a treatment for patients with acute myeloid leukemia.

Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, Department of Medicine, The University of British Columbia, discusses the efficacy of induction therapy with bendamustine plus rituximab (Rituxan) in mantle cell lymphoma (MCL).

Howard A. "Skip" Burris, III, MD, FASCO, FACP, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019-2020 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses investigational immunotherapy approaches in triple-negative breast cancer (TNBC).

Jennifer Woyach, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses the design of the ongoing phase III Alliance A041702 trial in chronic lymphocytic leukemia (CLL).

Joshua M. Lawrenz, MD, discusses patient feedback of a study on preoperative 5-fraction radiation therapy for soft tissue sarcoma with immediate resection.

Katherine Crew, MD, MS, discusses new research in the advanced HER2-positive breast cancer landscape.

Kathryn E. Beckermann, MD, PhD, discusses investigational treatment strategies in metastatic renal cell carcinoma.

Shebli Atrash, MD, discusses the results of the BELLINI trial examining patients with relapsed/refractory multiple myeloma.

Ajjai Shivaram Alva, MBBS, discusses the results of the CABOSUN trial in renal cell carcinoma.

Akshjot Puri, MD, discusses challenges facing older patients with pancreatic cancer.

Ankit Kansagra, MD, discusses the expanding role of CAR T-cell therapy in lymphoma and multiple myeloma.

Prapti Patel, MD, discusses delaying treatment until after genetic testing in elderly patients with newly diagnosed acute myeloid leukemia.

Sam S. Chang, MD, MBA, discusses adjuvant versus salvage radiation in patients with nonmetastatic high-risk prostate cancer.

Dawn Hershman, MD, MS, professor of medicine and epidemiology, leader of the Breast Cancer Program of the Herbert Irving Comprehensive Cancer Center at Columbia University, discusses the use of endocrine therapy in premenopausal women with early-stage hormone receptor (HR)–positive, HER2-negative breast cancer.

Matthew S. Davids, MD, MMSc, director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses exciting data with acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).

Andre H. Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the utility of novel agents in mantle cell lymphoma (MCL).

Amir Khan, MD, discusses the rising incidence of gastric and colorectal cancers in young adult patients.

Naoto Ueno, MD, PhD, FACP, discusses residual cancer burden and immunotherapy in inflammatory breast cancer.

OncLive interviewed experts at the State of the Science Summits™ in January 2020 on what they are going to work on improving in clinical practice this year.

Noa Biran, MD, physician, discusses elotuzumab (Empliciti) as post-autologous stem cell transplant consolidation in patients with high-risk myeloma.